Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Zander

Showing results (181-190 of 206) with videos related to

Pageof 21
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 21, 2022
Microsatellite instability and sex differences in resectable gastric cancer - A pooled analysis of three European cohortsAlexander Quaas, Hedde D Biesma, Anna D Wagner, et al.
JCO Precision Oncology|February 1, 2022
Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR AlterationsDavid M Hyman, Ben Tran, Luis Paz-Ares, et al.
Future Oncology (London, England)|March 15, 2023
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagusYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.
Oncotarget|December 5, 2014
PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignanciesMatthias Scheffler, Marc Bos, Masyar Gardizi, et al.
Nature|March 24, 2022
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancerKohei Shitara, Jaffer A Ajani, Markus Moehler, et al.
Journal of Cancer Research and Clinical Oncology|January 18, 2025
Correction: Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemicVolker Arndt, Daniela Doege, Stefan Fröhling, et al.
Lancet (London, England)|June 8, 2021
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 12, 2012
Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancerHans-Ulrich Schildhaus, Lukas C Heukamp, Sabine Merkelbach-Bruse, et al.
Journal of Cancer Research and Clinical Oncology|October 14, 2022
Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemicVolker Arndt, Daniela Doege, Stefan Fröhling, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 7, 2009
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancerMartin L Sos, Stefanie Fischer, Roland Ullrich, et al.
Pageof 21

Showing results (181-190 of 206) with videos related to

Sort By:
Pageof 21
European Journal of Cancer (Oxford, England : 1990)|July 21, 2022
Microsatellite instability and sex differences in resectable gastric cancer - A pooled analysis of three European cohortsAlexander Quaas, Hedde D Biesma, Anna D Wagner, et al.
JCO Precision Oncology|February 1, 2022
Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR AlterationsDavid M Hyman, Ben Tran, Luis Paz-Ares, et al.
Future Oncology (London, England)|March 15, 2023
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagusYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.
Oncotarget|December 5, 2014
PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignanciesMatthias Scheffler, Marc Bos, Masyar Gardizi, et al.
Nature|March 24, 2022
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancerKohei Shitara, Jaffer A Ajani, Markus Moehler, et al.
Journal of Cancer Research and Clinical Oncology|January 18, 2025
Correction: Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemicVolker Arndt, Daniela Doege, Stefan Fröhling, et al.
Lancet (London, England)|June 8, 2021
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 12, 2012
Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancerHans-Ulrich Schildhaus, Lukas C Heukamp, Sabine Merkelbach-Bruse, et al.
Journal of Cancer Research and Clinical Oncology|October 14, 2022
Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemicVolker Arndt, Daniela Doege, Stefan Fröhling, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 7, 2009
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancerMartin L Sos, Stefanie Fischer, Roland Ullrich, et al.
Pageof 21